Zhejiang Taimei Medical Technology Forms RMB227 Million Venture Capital Partnership

Reuters2025-12-24

Zhejiang Taimei Medical Technology Forms RMB227 Million Venture Capital Partnership

Zhejiang Taimei Medical Technology Co., Ltd. has announced the formation of a new partnership, Jiaxing Kaifeng Taimei Innovative Venture Capital Partnership (Limited Partnership), together with Taimei Intelligence, Jiaxing Industry Fund, Mr. Lu Gaofeng, Ms. Lu Haixiao, and Ms. Chen Guojuan. The total initial capital contribution for the partnership is RMB227.27 million, with Zhejiang Taimei contributing RMB70 million. The partnership, which has an initial term of seven years, will focus on equity investment in innovative pharmaceutical companies, particularly those at early to growth stages. Kaifeng Taimei will serve as the general partner, while the other parties, including Zhejiang Taimei, will participate as limited partners.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Zhejiang Taimei Medical Technology Co. Ltd. published the original content used to generate this news brief via IIS, the Issuer Information Service operated by the Hong Kong Stock Exchange (HKex) (Ref. ID: HKEX-EPS-20251224-11967274), on December 24, 2025, and is solely responsible for the information contained therein.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2593471347?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-12-24 19:34","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2593471347","market":"nz","top_or_hot":-1,"title":"Zhejiang Taimei Medical Technology Forms RMB227 Million Venture Capital Partnership","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Zhejiang Taimei Medical Technology Forms RMB227 Million Venture Capital Partnership\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Zhejiang Taimei Medical Technology Co., Ltd. has announced the formation of a new partnership, Jiaxing Kaifeng Taimei Innovative Venture Capital Partnership (Limited Partnership), together with Taimei Intelligence, Jiaxing Industry Fund, Mr. Lu Gaofeng, Ms. Lu Haixiao, and Ms. Chen Guojuan. The total initial capital contribution for the partnership is RMB227.27 million, with Zhejiang Taimei contributing RMB70 million. The partnership, which has an initial term of seven years, will focus on equity investment in innovative pharmaceutical companies, particularly those at early to growth stages. Kaifeng Taimei will serve as the general partner, while the other parties, including Zhejiang Taimei, will participate as limited partners.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n<i>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Zhejiang Taimei Medical Technology Co. Ltd. published the original content used to generate this news brief via IIS, the Issuer Information Service operated by the Hong Kong Stock Exchange (HKex) (Ref. ID: HKEX-EPS-20251224-11967274), on December 24, 2025, and is solely responsible for the information contained therein.</span></i>\n</p>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Zhejiang Taimei Medical Technology Forms RMB227 Million Venture Capital Partnership</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nZhejiang Taimei Medical Technology Forms RMB227 Million Venture Capital Partnership\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-12-24 19:34</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Zhejiang Taimei Medical Technology Forms RMB227 Million Venture Capital Partnership\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Zhejiang Taimei Medical Technology Co., Ltd. has announced the formation of a new partnership, Jiaxing Kaifeng Taimei Innovative Venture Capital Partnership (Limited Partnership), together with Taimei Intelligence, Jiaxing Industry Fund, Mr. Lu Gaofeng, Ms. Lu Haixiao, and Ms. Chen Guojuan. The total initial capital contribution for the partnership is RMB227.27 million, with Zhejiang Taimei contributing RMB70 million. The partnership, which has an initial term of seven years, will focus on equity investment in innovative pharmaceutical companies, particularly those at early to growth stages. Kaifeng Taimei will serve as the general partner, while the other parties, including Zhejiang Taimei, will participate as limited partners.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n<i>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Zhejiang Taimei Medical Technology Co. Ltd. published the original content used to generate this news brief via IIS, the Issuer Information Service operated by the Hong Kong Stock Exchange (HKex) (Ref. ID: HKEX-EPS-20251224-11967274), on December 24, 2025, and is solely responsible for the information contained therein.</span></i>\n</p>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"02576","symbol_name":"太美医疗科技","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251224:nNDL6PpFWW:1","article_id":"2593471347","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2593471347","pubTimestamp":1766576094,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Zhejiang Taimei Medical Technology Co., Ltd. has announced the formation of a new partnership, Jiaxing Kaifeng Taimei Innovative Venture Capital Partnership , together with Taimei Intelligence, Jiaxing Industry Fund, Mr. Lu Gaofeng, Ms. Lu Haixiao, and Ms. Chen Guojuan. The total initial capital contribution for the partnership is RMB227.27 million, with Zhejiang Taimei contributing RMB70 million. The partnership, which has an initial term of seven years, will focus on equity investment in innovative pharmaceutical companies, particularly those at early to growth stages. Kaifeng Taimei will serve as the general partner, while the other parties, including Zhejiang Taimei, will participate as limited partners.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investmen","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"02576":"太美医疗科技","BK1141":"生命科学工具和服务"},"translate_title":"浙江太美医疗科技成立人民币2.27亿元创投合伙企业","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"02576":0.9},"content_text":"Zhejiang Taimei Medical Technology Forms RMB227 Million Venture Capital Partnership\n    \n\n        Zhejiang Taimei Medical Technology Co., Ltd. has announced the formation of a new partnership, Jiaxing Kaifeng Taimei Innovative Venture Capital Partnership (Limited Partnership), together with Taimei Intelligence, Jiaxing Industry Fund, Mr. Lu Gaofeng, Ms. Lu Haixiao, and Ms. Chen Guojuan. The total initial capital contribution for the partnership is RMB227.27 million, with Zhejiang Taimei contributing RMB70 million. The partnership, which has an initial term of seven years, will focus on equity investment in innovative pharmaceutical companies, particularly those at early to growth stages. Kaifeng Taimei will serve as the general partner, while the other parties, including Zhejiang Taimei, will participate as limited partners.\n      \n\n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Zhejiang Taimei Medical Technology Co. Ltd. published the original content used to generate this news brief via IIS, the Issuer Information Service operated by the Hong Kong Stock Exchange (HKex) (Ref. ID: HKEX-EPS-20251224-11967274), on December 24, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"corporation","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.0","shortVersion":"4.36.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2593471347","isCrawlerRequest":true}